title: Autologous stem cell transplantation for advanced acute myeloid leukemia.
abstract: We studied the efficacy of a two-step approach to autologous stem cell transplantation for patients with advanced acute myeloid leukemia. Step 1 consisted of consolidation chemotherapy using cytarabine 2000 mg/m(2) twice daily for 4 days plus etoposide 40 mg/kg by continuous infusion over the same 4 days. Peripheral blood stem cells were collected under granulocyte colony-stimulating factor (G-CSF) stimulation during recovery from this chemotherapy. Step 2, autologous stem cell transplantation, utilized the preparative regimen of oral busulfan 16 mg/kg followed by etoposide 60 mg/kg i.v. During step 1, there were no treatment-related deaths among 28 patients, but two patients did not proceed to transplantation because of failure of mobilization. A median CD34+ dose (x10(6)/kg) of 13.6 was collected. Of 26 patients undergoing autologous transplant, there was one treatment-related death and 12 relapses. With a median follow-up of 5.4 years, 5 year event-free survival (EFS) of all patients entered is 54%. The most important prognostic factor was cytogenetic changes. All seven patients with t(15,17) remained in long-term remission whereas EFS for other patients was 38%. We conclude that this two-step approach to autologous transplantation produces excellent stem cell yields, allows a high percentage of patients to receive the intended therapy, and provides effective treatment.
authors.affiliation: University of California, San Francisco, CA, USA.
authors.forename: C A
authors.initials: CA
authors.lastname: Linker
authors.forename: L E
authors.initials: LE
authors.lastname: Damon
authors.forename: C A
authors.initials: CA
authors.lastname: Ries
authors.forename: W A
authors.initials: WA
authors.lastname: Navarro
authors.forename: D
authors.initials: D
authors.lastname: Case
authors.forename: J L
authors.initials: JL
authors.lastname: Wolf
mesh_terms: D000328:Adult; D000368:Aged; D018952:Antigens, CD34 / Q000378:metabolism; D000971:Antineoplastic Combined Chemotherapy Protocols; D002066:Busulfan / Q000008:administration & dosage; D002452:Cell Count; D002884:Chromosomes, Human, Pair 15; D002886:Chromosomes, Human, Pair 17; D003561:Cytarabine / Q000008:administration & dosage; D003582:Cytogenetics; D018572:Disease-Free Survival; D005047:Etoposide / Q000008:administration & dosage; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage; D019650:Hematopoietic Stem Cell Mobilization / Q000379:methods; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy / Q000235:genetics / Q000628:therapy*; D008875:Middle Aged; D011379:Prognosis; D014178:Translocation, Genetic; D014182:Transplantation, Autologous
chemical_list: D018952:Antigens, CD34; D003561:Cytarabine; D016179:Granulocyte Colony-Stimulating Factor; D005047:Etoposide; D002066:Busulfan